Adel Sadeq

Adel Sadeq

Auto-generated profile, based on publicly available information

Adel Sadeq

Program of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, United Arab Emirates

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
NENermin Eissa
Nermin Eissa
MAMohammed Al-Houqani
Mohammed Al-Houqani
ASAdel Sadeq
Adel Sadeq
Shreesh  OjhaShreesh Ojha
Shreesh Ojha
ASAstrid Sasse
Astrid Sasse
Bassem SadekBassem Sadek
Bassem Sadek
Autistic Spectrum Disorder (ASD) is a complex neurodevelopmental brain disorder characterized by two core behavioral symptoms, namely impairments in social communication and restricted/repetitive behavior. The molecular mechanisms underlying ASD are not well understood. Recent genetic as well as non-genetic animal models contributed significantly in understanding the pathophysiology of ASD, as they establish autism-like behavior in mice and rats. Among the genetic causes, several chromosomal mutations including duplications or deletions could be possible causative factors of ASD. In addition, the biochemical basis suggests that several brain neurotransmitters, e.g., dopamine (DA), serotonin (5-HT), gamma-amino butyric acid (GABA), acetylcholine (ACh), glutamate (Glu) and histamine (HA) participate in the onset and progression of ASD. Despite of convincible understanding, risperidone and aripiprazole are the only two drugs available clinically for improving behavioral symptoms of ASD following approval by Food and Drug Administration (FDA). Till date, up to our knowledge there is no other drug approved for clinical usage specifically for ASD symptoms. However, many novel drug candidates and classes of compounds are underway for ASD at different phases of preclinical and clinical drug development. In this review, the diversity of numerous aetiological factors and the alterations in variety of neurotransmitter generation, release and function linked to ASD are discussed with focus on drugs currently used to manage neuropsychiatric symptoms related to ASD. The review also highlights the clinical development of drugs with emphasis on their pharmacological targets aiming at improving core symptoms in ASD.

1 October 2016 in Behavioural Brain Research
Verified
Journal Article
Closed access
Bassem SadekBassem Sadek
Bassem Sadek
ASAli Saad
Ali Saad
ASAdel Sadeq
Adel Sadeq
FJFakhreya Jalal
Fakhreya Jalal
HSHolger Stark
Holger Stark

16 June 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
NENermin Eissa
Nermin Eissa
ASAdel Sadeq
Adel Sadeq
ASAstrid Sasse
Astrid Sasse
Bassem SadekBassem Sadek
Bassem Sadek
Many behavioral and psychological symptoms of dementia (BPSD) share similarities in executive functioning and communication deficits with those described in several neuropsychiatric disorders, including Alzheimer’s disease (AD), epilepsy, schizophrenia (SCH), and autism spectrum disorder (ASD). Numerous studies over the last four decades have documented altered neuroinflammation among individuals diagnosed with ASD. The purpose of this revie\w is to examine the hypothesis that\ central histamine (HA) plays a significant role in the regulation of neuroinflammatory processes of microglia functions in numerous neuropsychiatric diseases, i.e., ASD, AD, SCH, and BPSD. In addition, this review summarizes the latest preclinical and clinical results that support the relevance of histamine H1-, H2-, and H3-receptor antagonists for the potential clinical use in ASD, SCH, AD, epilepsy, and BPSD, based on the substantial symptomatic overlap between these disorders with regards to cognitive dysfunction. The review focuses on the histaminergic neurotransmission as relevant in these brain disorders, as well as the effects of a variety of H3R antagonists in animal models and in clinical studies.

18 May 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
AAAlaa Alachkar
Alaa Alachkar
Shreesh  OjhaShreesh Ojha
Shreesh Ojha
ASAdel Sadeq
Adel Sadeq
AAAbdu Adem
Abdu Adem
AFAnnika Frank
Annika Frank
Bassem SadekBassem Sadek
Bassem Sadek
: Epilepsy is a chronic neurological disorder characterized by irregular, excessive neuronal excitability, and recurrent seizures that affect millions of patients worldwide. Currently, accessible antiepileptic drugs (AEDs) do not adequately support all epilepsy patients, with around 30% patients not responding to the existing therapies. As lifelong epilepsy treatment is essential, the search for new and more effective AEDs with an enhanced safety profile is a significant therapeutic goal. Seizures are a combination of electrical and behavioral events that can induce biochemical, molecular, and anatomic changes. Therefore, appropriate animal models are required to evaluate novel potential AEDs. Among the large number of available animal models of seizures, the acute pentylenetetrazole (PTZ)-induced myoclonic seizure model is the most widely used model assessing the anticonvulsant effect of prospective AEDs, whereas chronic PTZ-kindled seizure models represent chronic models in which the repeated administration of PTZ at subconvulsive doses leads to the intensification of seizure activity or enhanced seizure susceptibility similar to that in human epilepsy. In this review, we summarized the memory deficits accompanying acute or chronic PTZ seizure models and how these deficits were evaluated applying several behavioral animal models. Furthermore, major advantages and limitations of the PTZ seizure models in the discovery of new AEDs were highlighted. With a focus on PTZ seizures, the major biochemicals, as well as morphological alterations and the modulated brain neurotransmitter levels associated with memory deficits have been illustrated. Moreover, numerous medicinal compounds with concurrent anticonvulsant, procognitive, antioxidant effects, modulating effects on several brain neurotransmitters in rodents, and several newly developed classes of compounds applying computer-aided drug design (CADD) have been under development as potential AEDs. The article details the in-silico approach following CADD, which can be utilized for generating libraries of novel compounds for AED discovery. Additionally, in vivo studies could be useful in demonstrating efficacy, safety, and novel mode of action of AEDs for further clinical development.

31 December 2023 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
PDF file
KAKhalid Awad Al-kubaisi
Khalid Awad Al-kubaisi
AEAsim Elnour
Asim Elnour
ASAdel Sadeq
Adel Sadeq
Continuing professional development (CPD) is essential for pharmacists to maintain and enhance their knowledge and skills. The purpose of this research was to collect data about the perception of pharmacists in the United Arab Emirates (UAE) towards CPD and identify factors that motivate or hinder their participation in different types of CPD activities. A cross-sectional survey was conducted among 322 pharmacists who completed a self-administered questionnaire that assessed their demographic characteristics, CPD preferences, motivators and obstacles to attending CPD programs, and perceived learning outcomes. Participants’ average age was 33 years (mean = 30.6, SD = 5.97), and the range of years, since they graduated from a pharmacy degree program was 18 years (mean = 10.9, SD = 4.8). More than half of the participants were female; 198 (61.5%) and 193 (59.9%) of them were married. The study found that married pharmacists (AOR = 0.5, 95% CI 0.266–0.939, P value = 0.031), older participants (AOR = 0.232, 95% CI 0.266–0.939, P value = 0.04), and those who graduated longer than 16 years ago were less likely to attend live CPD events (AOR = 0.454, 95% CI 0.22–0.924). However, participants who worked up to 15 h had higher odds of attending live CPD events (AOR = 3.511, 95% CI 1.117–11.039, P value: 0.026). In addition, female pharmacists were less likely to participate in computer/internet-based continuing education than male pharmacists (AOR = 0.038, 95% CI 0.293–0.965, P value = 0.038). It also revealed that pharmacists who were not motivated by the topic of the CPD activity had a higher chance of attending computer/internet-based format (AOR = 2.289, 95% CI 1.198–4.371, P value = 0.012). In contrast, those who did not report the long distance to the CPD site as a hindrance had a lower likelihood of attending online internet-based CPD (AOR = 0.548, 95% CI 0.319–0.941, P value = 0.029). This study is the first to explore pharmacists’ predictors of attending different CPD activities. These predictors are gender, age, marital status, experience since graduation, working hours, family barriers, work responsibilities, interest in the presentation topic, and the long travel distance to the site. These findings suggest that pharmacists have unique challenges and motivations regarding continuing education and that tailored approaches may be necessary to encourage participation.

19 May 2015 in Journal of the Saudi Heart Association
Verified
Journal Article
Open access
ASAbdulla Shehab
Abdulla Shehab
AEAsim Elnour
Asim Elnour
Akshaya BhagavathulaAkshaya Bhagavathula
Akshaya Bhagavathula
PEPınar Erkekoglu
Pınar Erkekoglu
FHFarah Hamad
Farah Hamad
AEAhmed Eltayeb Yousif Ahmed Eltayeb
Ahmed Eltayeb Yousif Ahmed Eltayeb